Novartis Touts Galvus Efficacy Vs. Januvia After Metformin Comparison Fails
Novartis is highlighting the superior efficacy of its dipeptidyl peptidase-4 inhibitor Galvus relative to Merck's recently launched DPP-4 agent Januvia.
Novartis is highlighting the superior efficacy of its dipeptidyl peptidase-4 inhibitor Galvus relative to Merck's recently launched DPP-4 agent Januvia.